Labcorp to acquire Toxikon, expanding nonclinical development testing capabilities for pharmaceutical, biotech and medical device clients

BURLINGTON, N.C. --(BUSINESS WIRE)--Nov. 18, 2021-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has entered into a definitive agreement to acquire Toxikon, a contract research organization delivering best-in-class nonclinical testing services. Once completed, the transaction will create a strategic footprint for Labcorp to partner with pharmaceutical and biotechnology clients in the Boston, Mass., area and bolster its strong nonclinical development portfolio.

Becoming a leader through the Project Management Academy

Gaining on-the-job experience to become a clinical project manager is now a lot easier with the Labcorp Project Management Academy.

Cancer testis antigen burden: A novel predictive biomarker for immunotherapy in solid tumors

Labcorp and National Kidney Foundation promote patient registry to enhance clinical trial accessibility, diversity

BURLINGTON, N.C. & NEW YORK --(BUSINESS WIRE)--Nov. 4, 2021-- Labcorp (NYSE: LH), a leading global life sciences company, and the National Kidney Foundation (NKF), the largest patient organization dedicated to the prevention and treatment of kidney disease, announced their collaboration to promote the NKF Patient Network, the first national registry for chronic kidney disease (CKD) patients in the U.S. The NKF Patient Network will offer greater data and insights to physicians, as well as improved clinical trial access for patients with kidney disease.